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Abstract
Background: Serum aminotransferase concentrations are reportedly strongly associated with
insulin resistance, an established cardiovascular risk factor that is not routinely assessed in clinical
practice. We therefore explored the possibility that serum aminotransferase concentrations are as
closely related to large artery disease as insulin resistance in rheumatoid arthritis (RA).
Methods: Carotid artery plaque (ultrasonography), insulin resistance and liver enzymes (prior to
methotrexate (MTX) were determined in 77 consecutive patients with RA (43 with and 34 without
MTX).
Results:  Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were
associated with insulin resistance in univariate analysis (R = 0.54, p < 0.0001 and R = 0.36, p = 0.001,
respectively) and after adjustment for age, gender and waist circumference (partial R = 0.43, p =
0.0001 and partial R = 0.37, p = 0.001, respectively). ALT and AST concentrations were higher in
patients with plaque as compared to in those without plaque (ALT (u/l): 27 [22-32] versus 20 [18-
23], p = 0.02; AST (u/l): 25 [21-28] versus 20 [19-22], p = 0.02). The odds ratios [95% CI] for plaque
were 1.92 [1.14–3.24] (p = 0.01), 1.93 [1.17–3.16] (p = 0.009) and 1.82 [1.13–2.93] (p = 0.01) for
1 SD increase in ALT (~10 u/l) and AST (~6 u/l) concentrations and in logarithmically transformed
homeostasis model assessment of insulin resistance (HOMA-IR) (~0.2 uU.mmol/ml.l), respectively.
After adjustment for the potentially confounding characteristics of age, sex, hypertension and
hypothyroidism in logistic regression models, ALT (p = 0.049) and AST concentrations (p = 0.027)
remained associated with plaque whereas the HOMA-IR did not (p = 0.08). AST concentrations (p
= 0.049) were associated with plaque independent of insulin resistance whereas the HOMA-IR (p
= 0.1) was not associated with plaque independent of AST concentrations.
Conclusion:  Within currently recommended reference ranges, serum aminotransferase
concentrations may be strongly associated with insulin resistance and atherosclerosis in patients
with RA. The measurement of aminotransferase concentrations could be a useful tool in
cardiovascular risk stratification in patients with RA.
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Background
Insulin resistance is a pathogenetic factor in the metabolic
syndrome [1], a constellation of interrelated risk factors
that confers a ~2-fold increase in the relative risk for
atherosclerotic cardiovascular disease events [2]. Insulin
resistance further predicts cardiovascular disease inde-
pendent of other metabolic syndrome features [3-7].
Rheumatoid arthritis (RA) patients experience a markedly
increased prevalence of cardiovascular disease [8-10], a
comorbidity that may be partly mediated through insulin
resistance [11-15]. Indeed, an independent association of
insulin resistance with carotid as well as coronary artery
atherosclerosis has been reported in RA [16,17]. However,
whereas insulin resistance formed part of the earlier
World Health Organization and the European Group for
the Study of Insulin Resistance defined metabolic syn-
drome, the more recent National Cholesterol Education
Program's Adult Treatment Panel III (NCEP:APTIII) and
the International Diabetes Federation defined metabolic
syndrome no longer include insulin resistance for routine
assessment of cardiovascular risk [1,18]. The arguments
against the use of insulin resistance include its lack of
standardization and the ease of measuring other charac-
teristics of the metabolic syndrome [1,18,19]. We and
others recently found that in contrast to the homeostasis
model assessment of insulin resistance (HOMA-IR)
[16,17], the NCEP:ATPIII defined metabolic syndrome
was not associated with carotid and coronary artery
atherosclerosis in a patients with RA. Therefore, outcome-
based studies should be performed to assess the value of
HOMA-IR in RA, or an alternative and more sensitive
approach should be devised to predict the impact of met-
abolic syndrome features on cardiovascular risk in RA.
Non-alcoholic fatty liver disease (NAFLD) constitutes a
newly recognized integral component of the metabolic
syndrome [20,21]. Indeed, magnetic resonance spectros-
copy quantified liver fat content is strongly associated
with insulin resistance and independent of overall body
fat content [22]. Further, elevated aminotransferases
(alanine aminotransferase (ALT) and aspartate ami-
notransferase (AST)) are surrogate markers of liver fat con-
tent [20,21] and analysis of the data from the Third
National Health and Nutrition Examination Survey
revealed a strong association of unexplained aminotrans-
ferase elevations with metabolic syndrome features [23].
Whether such relationships exist in patients with RA has
not been reported. Importantly, in a 10-year follow-up
study, baseline ALT concentrations predicted cardiovascu-
lar events [24]. Therefore, since insulin resistance is asso-
ciated with atherosclerosis whereas serum
aminotransferase concentrations are associated with insu-
lin resistance and predict cardiovascular events, it is possi-
ble that the respective liver enzymes are equivalent to
insulin resistance in their ability to identify subjects with
atherosclerosis. If so, serum aminotransferases could be as
useful in cardiovascular risk stratification as the assess-
ment of insulin resistance. In the present study, we there-
fore explored the relationship between serum
aminotransferase concentrations and metabolic syn-
drome features and determined whether serum ami-
notransferase concentrations are as strongly associated
with ultrasonographically located carotid artery atheroma
as insulin resistance in RA patients in whom liver function
tests would normally be conducted as part of routine
assessments.
Methods
Patients
We investigated 77 consecutive patients that met the
American College of Rheumatology criteria for RA [25].
Their demographics are shown in Table 1. Patients with
raised ALT or AST levels (> 35 u/l for ALT and > 34 u/l for
AST in women, and > 45 u/l for ALT and > 44 u/l for AST
in men, in our laboratory) were excluded if they also had
circulating hepatitis B surface antigen or hepatitis C anti-
body, serological evidence of autoimmune hepatitis
(presence of circulating antinuclear, anti smooth-muscle
and/or anti liver-kidney microsomal-1 antibodies) or an
increased transferrin saturation that may represent hemo-
chromatosis [26]. Other exclusion criteria comprised the
use of lipid or glucose lowering agents or medications
other than antirheumatic agents that can affect ami-
notransferase levels. Three patients had diabetes [27] that
was managed with dietary intervention only. Since the
intake of as little as one alcoholic drink per day in women
(83% of our cohort) can increase aminotransferase con-
centrations [23] and mild and moderate alcohol intake
are common in our setting, we did not exclude patients
that used alcohol but controlled for alcohol consumption
in our analyses. Also, we did not exclude patients with
hypothyroidism when they were euthyroid on replace-
ment therapy at the time of the study. Informed consent
was obtained from each patient and the study was
approved by The Ethics Committee for Research on
Human Subjects (Medical) of the University of the Witwa-
tersrand.
Clinical and laboratory data and carotid ultrasonography
These data (Tables 1 and 2) were obtained through
patient interview, physical examination, medical record
review and laboratory tests performed on fasting blood
samples. We recorded life style factors, RA characteristics
and other traditional and nontraditional risk factors
(Table 1). Hypertension was diagnosed in patients with a
blood pressure of ≥140/90 mmHg and in those employ-
ing antihypertensive agents. We measured high-sensitivity
C-reactive protein and lipid levels, plasma glucose, serum
insulin and thyrotropin concentrations [28]. Insulin
resistance was estimated by the homeostasis model assess-BMC Cardiovascular Disorders 2007, 7:31 http://www.biomedcentral.com/1471-2261/7/31
Page 3 of 10
(page number not for citation purposes)
ment of insulin resistance (HOMA-IR) using the formula
= (insulin (uU/ml) × glucose (mmol/l)) ÷ 22.5 [29]. Dia-
betes was diagnosed in accordance with the recent recom-
mendations as made by the American Diabetes
Association [27].
Carotid artery plaque was defined as a localized irregular
intima-media thickening of ≥1.5 mm as identified by high
resolution B-mode ultrasonography (Image Point,
Hewlett Packard Andover, MA, USA). We also measured
the common carotid artery intima-media thickness more
than 1 cm proximal to the common carotid artery flow
divider. All ultrasonographic evaluations were performed
by the same investigator who was unaware of the CV risk
factor profiles of the patients. The coefficient of variation
for the intraobserver variability was 5.7% and further
details of carotid artery ultrasonography in our unit have
been previously reported on [28].
ALT and AST concentrations were determined using the α-
ketoglutarate reaction (Abbott Laboratories, Diagnostic
Division, Abbott Park, Illinois 60064). Of the 77 patients,
34 were methotrexate naïve and 43 were using methotrex-
ate (Table 2). ALT and AST concentrations were measured
in all patients at the time that carotid artery ultrasonogra-
phy was performed. Additionally, in patients using meth-
otrexate, aminotransferase concentrations had been
recorded immediately prior to methotrexate initiation
and, in the respective patients, these levels were used in
the main analyses of this report. Since weight loss and
weight gain are both associated with changes in ami-
notransferase concentrations and dietary advice is rou-
tinely provided in our setting [15], we also determined
changes in weight during methotrexate therapy. Finally,
drug therapy that was used prior to methotrexate initia-
tion was also recorded.
Table 1: Baseline characteristics in 77 rheumatoid arthritis patients. Values are mean [95% CI] or n (%).
Characteristic All patients (n = 77) Patients with plaque (n = 25) Patients without plaque (n = 52) p†
Age (years) 54 [51–56] 60 [57–63] 51 [48–54] 0.0002
Women 64 (83) 21 (84) 43 (83) 0.9
Caucasian: Asian 69 (90): 8 (10) 23 (92): 2 (8) 46 (88): 6 (12) 0.6
Life style factors
Current smokers 17 (22) 8 (32) 9 (17) 0.2
Current smoking (cigarettes/day)* 0.8 [0.4–1.4] 1.5 [0.4–3.3] 0.6 [0.2–1.2] 0.2
Current alcohol users 26 (34) 9 (36) 17 (33) 0.8
Current alcohol (units/week)* 1 [0.6–1.6] 1.2 [0.4–2.6] 1.0 [0.4–1.7] 0.7
Current exercisers 22 (29) 6 (25) 16 (31) 0.6
Exercise (hours/week)* 0.5 [0.3–0.8] 0.4 [0.1–0.9] 0.6 [0.3–0.9] 0.6
Disease duration (years)* 6.6 [4.9–8.7] 9.2 [5.6–15.2] 5.6 [4.0–7.8] 0.1
Rheumatoid factor positive 61 (79) 19 (76) 42 (81) 0.6
Acute phase reactants
Hs-C-reactive protein (mg/l)* 7.4 [5.4–10.2] 9.4 [5.8–15.2] 6.7 [4.3–10.2] 0.3
ESR (mm/hr)* 14 [10–18] 11 [7–17] 15 [10–21] 0.3
Other cardiovascular risk factors
Waist circumference (cm) 86 [83–88] 88 [83–93] 85 [81–88] 0.3
Body mass index (kg/m2) 24.4 [23.4–25.3] 24.2 [22.8–26.0] 24.3 [23.1–25.6] 0.9
Hypertension 34 (44) 19 (76) 15 (29) 0.0002
Systolic blood pressure (mmHg) 127 [124–131] 131 [124–138] 125 [121–129] 0.1
Diastolic blood pressure (mmHg) 82 [80–84] 81 [78–85] 82 [80–85] 0.6
Total cholesterol (mmol/l) 5.1 [4.9–5.3] 5.0 [4.6–5.3] 5.1 [4.9–5.4] 0.5
LDL cholesterol (mmol/l) 2.9 [2.7–3.0] 2.8 [2.5–3.1] 2.9 [2.7–3.1] 0.5
HDL cholesterol (mmol/l) 1.6 [1.5–1.7] 1.7 [1.5–1.9] 1.6 [1.5–1.7] 0.5
Triglycerides (mmol/l)* 1.1 [1.0–1.2] 1.2 [1.0–1.4] 1.0 [0.9–1.1] 0.08
HOMA-IR (uU.mmol/ml.l)* 1.15 [1.02–1.29] 1.45 [1.18–1.77] 1.03 [0.90–1.19] 0.009
Glucose (mmol/l) 4.3 [4.2–4.5] 4.3 [4.2–4.5] 4.5 [4.2–4.5] 0.8
Diabetes 3 (4) 0 (0) 3 (6) 0.3
Hypothyroidism 19 (25) 10 (40) 9 (17) 0.03
Framingham score* 4 [4–5] 6 [5–8] 4 [3–5] 0.009
CCA intima-media thickness (mm) 0.65 [0.63–0.68] 0.73 [0.69–0.78] 0.62 [0.60–0.64] 0.0001
CI, confidence interval; Hs, high sensitivity; ESR, erythrocyte sedimentation rate; LDL, low density lipoprotein; HDL, high density lipoprotein; 
HOMA-IR, homeostasis model assessment of insulin resistance; CCA, common carotid artery.
*Variables for which geometric means [95% CI] are given. †For comparison of characteristics between patients with plaque and patients without 
plaque.BMC Cardiovascular Disorders 2007, 7:31 http://www.biomedcentral.com/1471-2261/7/31
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Statistical analysis
Results were expressed as mean [95% confidence interval
(CI)] or number (%) unless indicated otherwise. For non-
normally distributed data, the geometric means [95% CI]
are given and these data were also logarithmically trans-
formed prior to statistical analysis.
We compared baseline recorded characteristics in patients
with and without plaque using the Student's t test for con-
tinuous variables and the chi-square test or the Fisher's
exact test for categorical variables.
Associations between aminotransferase levels and meta-
bolic syndrome features were assessed in simple and
mixed regression models or by the Student's t test and in
logistic regression models, as appropriate. Whether ami-
notransferase concentrations contribute to the variability
in insulin resistance independent of abdominal obesity
was also determined in mixed regression models. Because
Table 2: Antirheumatic agents and aminotransferase concentrations in 77 rheumatoid arthritis patients
Characteristic Mean [95% CI] or n (%)
Antirheumatic agents in 34 methotrexate naïve patients
Non-steroidal antiinflammatory agents 14 (41)
Prednisone users 4 (12)
Prednisone dose (mg/l)* 1.2 [1.0–1.4]
Disease modifying agents
Users 13 (38)
Leflunomide 6 (18)
Chloroquine 5 (15)
Sulphasalazine 3 (9)
Azathioprine 2 (6)
Antirheumatic agents in 43 patients before methotrexate use
Non-steroidal antiinflammatory agents 32 (74)
Prednisone users 17 (40)
Prednisone dose (mg/l)* 2.4 [1.7–3.4]
Disease modifying agents
Users 13 (30)
Sulphasalazine 10 (23)
Chloroquine 3 (7)
Antirheumatic agents in 43 patients using methotrexate
Non-steroidal antiinflammatory agents 20 (48)
Prednisone users 7 (16)
Prednisone dose (mg/l)* 1.0 [1.1–1.5]
Disease modifying agents
Methotrexate dose (mg/week) 19.6 [17.5–21.7]
Chloroquine 21 (49)
Minocyclin 12 (28)
Leflunomide 5 (12)
Sulphasalazine 4 (9)
Azathioprine 3 (7)
Aminotransferase levels in 34 methotrexate naïve patients
Alanine aminotransferase (u/l) 27 [22–31]
Aspartate aminotransferase (u/l) 23 [22–25]
Aminotransferase levels in 43 patients before methotrexate 
use
Alanine aminotransferase (u/l) 19 [17–22]
Aspartate aminotransferase (u/l) 20 [18–22]
Aminotransferase levels in 43 patients using methotrexate
Alanine aminotransferase (u/l) 38 [33–42]
Aspartate aminotransferase (u/l) 30 [27–34]
Increases in aminotransferase levels in 43 patients on 
methotrexate
Alanine aminotransferase (u/l) 18 [14–23]†
Aspartate aminotransferase (u/l) 11 [7–14]†
Change in weight in 43 patients since using methotrexate (kg) -0.7 [-0.2–0.6]‡
Duration of methotrexate therapy in 43 patients (years) 5.1 [4.1–6.1]
*Variables for which geometric means [95% CI] are given. †p < 0.0001; ‡p = 0.7.BMC Cardiovascular Disorders 2007, 7:31 http://www.biomedcentral.com/1471-2261/7/31
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many univariate analyses were performed, we verified
univariate associations in multivariable regression models
with consideration of interactions, collinearity and cau-
sality in which significance was set at 0.05.
The associations between aminotransferase concentra-
tions and plaque were assessed by the Student's t test and
subsequently in logistic regression models with entering
of a one standard deviation (SD) increase in ALT or AST
concentrations with or without potentially confounding
characteristics, as independent variables in the model.
Similar models were built to assess the associations of
HOMA-IR and waist circumference with plaque. Since 25
patients had plaque, we took into account that entering a
large number of independent variables in logistic regres-
sion models may constitute overfitting [30].
In studies performed on large numbers of RA patients,
carotid intima-media thickness was shown to be associ-
ated with an extensive number of cardiovascular risk fac-
tors [31,32]. In view of our small sample size, we did not
systematically assess the association of cardiovascular risk
factors with common carotid artery intima-media thick-
ness.
Results
Descriptive data
Descriptive data are shown in Tables 1 and 2. Of note, 26
(34%) patients consumed alcohol (Table 1). The number
of units of alcohol used per week in these patients was 1
in 2, 2 in 3, 3 in 2, 4 in 3, 6 in 2, 7 in 2, 8 in 1, 10 in 2, 11
in 1, 14 in 2, 20 in 1, 21 in 2, 26 in 1, 28 in 1 and 35 in 1
patient, respectively. In keeping with previous reports by
us [16,28], plaque was associated with age (p = 0.0002),
hypertension (p = 0.0002), the HOMA-IR (p = 0.0009),
hypothyroidism (p = 0.03) and the Framingham score (p
= 0.009). The mean common carotid artery intima-media
was 0.13 mm thicker in patients with plaque as compared
to in those without plaque (p = 0.0001). While not on
methotrexate, raised ALT and AST concentrations were
present in 5 patients and 1 patient, respectively, and the
highest ALT value was 63 u/l whereas that of AST was 40
u/l (Table 2). Upon the use of methotrexate, there was no
change in body weight whereas serum ALT concentrations
increased by 18 [14-23] u/l and AST concentrations by 11
[7-14] u/l (Table 2). Of the 43 patients on methotrexate,
16 experienced increased ALT levels and 6 increased AST
levels, and the highest ALT value was 83 u/l whereas that
of AST was 61 u/l. All 43 patients on methotrexate were
using folic acid and in them, aminotransferase levels that
were used in the main analysis (see methods) had been
measured 5.1 [4.1–6.1] years previously (see duration of
methotrexate therapy in Table 2).
Relationship between aminotransferase concentrations 
and metabolic syndrome features
Associations between aminotransferase concentrations
(those measured at the time that carotid artery ultrasonog-
raphy was performed in methotrexate naïve patients and
those measured immediately prior to methotrexate ther-
apy in the other patients (see methods)) and metabolic
syndrome features are shown in Table 3. ALT concentra-
tions were associated with insulin resistance, triglyceride
levels and waist circumference. AST concentrations were
also associated with insulin resistance and triglyceride lev-
els but not with waist circumference. Neither ALT nor AST
concentrations were associated with glucose and HDL
cholesterol levels and systolic and diastolic blood pres-
sure. Aminotransferase levels were also not associated
with a diagnosis of hypertension (ALT = 25 [21-29] u/l in
hypertensives and 21 [18-24] u/l in normotensives (p =
0.10); AST = 23 [20-26] u/l in hypertensives and 21 [19-
23] in normotensives (p = 0.13)). With regard to potential
confounding characteristics in this context, aminotrans-
ferase concentrations were not associated with the use of
non-steroidal antiinflammatory agents (ALT = 21 [18-23]
u/l in users (n = 46 (60%)) and 23 [20-27] u/l in non-
users (p = 0.4); AST = 21 [19-23] u/l in users and 22 [20-
24] u/l in non-users (p = 0.4)) and with the use of leflu-
nomide (ALT = 25 [21-30] u/l in users (n = 6 (8%)) and
ALT = 22 [19-25] u/l in non-users (p = 0.2); AST = 23 [19-
27] u/l in users and AST = 21 [20-23] u/l in non-users (p
= 0.3)). In separate multivariable models in which the use
of non-steroidal antiinflammatory agents or leflunomide
were adjusted for, ALT concentrations remained associ-
ated with the log HOMA-IR (p < 0.0001), waist circumfer-
ence (p ≤ 0.0003) and log triglycerides (p ≤ 0.0002), and
AST concentrations remained associated with log HOMA-
IR (p ≤ 0.002) and log triglycerides (p ≤ 0.001). Other
potential confounding characteristics in this context com-
prise alcohol use, changes in weight on methotrexate, age,
gender, use of glucocorticoids, minocyclin, sulphasala-
zine and azathioprine, systemic inflammation as reflected
by C-reactive protein concentrations and the erythrocyte
sedimentation rate, and hypothyroidism [20,33-37].
None of these variables were associated with aminotrans-
ferase concentrations (p ≥ 0.1). In separate multivariable
models in which these characteristics were adjusted for,
ALT remained associated with log HOMA-IR (p < 0.0001),
waist circumference (p ≤ 0.0007) and log triglycerides (p
≤ 0.0004), and AST concentrations remained associated
with log HOMA-IR (p ≤ 0.002) and log triglycerides (p ≤
0.002).
ALT concentrations while taking methotrexate were still
associated the HOMA-IR (R = 0.34, p = 0.03) but no
longer with other metabolic syndrome features (p ≥ 0.09).
AST concentrations on methotrexate were no longer asso-BMC Cardiovascular Disorders 2007, 7:31 http://www.biomedcentral.com/1471-2261/7/31
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ciated with any of the metabolic syndrome features (p ≥
0.09).
The relative contribution of aminotransferase 
concentrations and abdominal adiposity to the variability 
in insulin resistance
In mixed regression models in which age and sex were
adjusted for, ALT and AST concentrations contributed to
the HOMA-IR independent of waist circumference (Table
4). The standardized regression coefficient (SE) for the
independent relationships between ALT concentrations
and insulin resistance and between AST concentrations
and insulin resistance were as large as that for the relation-
ship between abdominal adiposity and insulin resistance
(p ≥ 0.2) thereby indicating that aminotransferase con-
centrations and abdominal adiposity contributed to the
variability of insulin resistance to a similar extent. ALT
and AST concentrations also contributed to the HOMA-IR
independent of the body mass index (p < 0.0001 and =
0.001, respectively).
ALT and AST concentrations while taking methotrexate
were not significantly associated with insulin resistance
independent of abdominal adiposity (partial R = 0.30; p =
0.06 and partial R = 0.28; p = 0.08, respectively). These
associations may not have been significant because of the
small sample size in which this analysis was performed,
i.e. only 43 patients were using methotrexate.
Relationships between aminotransferase concentrations 
and carotid artery atherosclerosis
ALT and AST concentrations were higher in patients with
plaque as compared to in those without plaque (ALT (u/
l): 27 [22-32] vs 20 [18-23], p = 0.02; AST (u/l): 25 [21-
28] vs 20 [19-22], p = 0.02). Using the 95% CI values of
ALT (23 u/l) and AST (22 u/l) in patients without plaque
as threshold values, having a high ALT or/and AST con-
centration (n = 41 (53%)) was associated with plaque
(odds ratio (OR) [95% CI] = 4.3 [1.5–12.8], p = 0.007).
The associations between aminotransferase concentra-
tions and carotid artery plaque were further assessed in
logistic regression models as illustrated in Figure 1. The
OR [95% CI] for plaque was 1.92 [1.14–3.24] (p = 0.01)
and 1.93 [1.17–3.16] (p = 0.009) for 1 SD increase in ALT
(~10 u/l) and AST concentrations (~6 u/l), respectively.
Adjustments for age, gender, hypertension and hypothy-
roidism did not materially affect the associations of ami-
notransferase concentrations with carotid artery plaque
(Figure 1). After adjustment for the Framingham score,
ALT and AST concentrations also remained associated
with plaque (OR [95% CI] = 1.92 [1.14–3.23] (p = 0.01)
and 2.05 [1.22–3.43] (p = 0.006) for 1 SD increase in ALT
and AST, respectively). Further, adjustment for alcohol
intake and changes in weight on MTX did not substan-
tially affect the associations of aminotransferase concen-
trations with common carotid artery plaque (p = 0.03 for
ALT and p = 0.02 for AST). After adjusting for insulin
resistance, AST concentrations remained associated with
plaque (p = 0.049). Aminotransferase concentrations
were not associated with CCA-IMT (R = 0.19, p = 0.1 for
ALT and R = 0.09, p = 0.4 for AST).
Aminotransferase concentrations in patients while taking
methotrexate were not associated with plaque (p = 0.2 for
both ALT and AST).
Abdominal adiposity and insulin resistance reportedly
constitute etiopathogenetic mechanisms in the metabolic
Table 4: Mixed regression models for insulin resistance (log HOMA-IR)
Model 1 (R2 = 0.40) Model 2 (R2 = 0.37)
ß ± SE stand ß ± SE pR P ß ± SE Stand ß ± SE pR P
Waist ÷ 10 (cm) 0.06 ± 0.02 0.29 ± 0.09 0.31 0.007 0.08 ± 0.02 0.42 ± 0.10 0.45 0.007
ALT ÷ 10 (u/l) 0.09 ± 0.02 0.41 ± 0.10 0.43 0.0001
AST÷ 10 (u/l) 0.12 ± 0.03 0.32 ± 0.09 0.37 0.001
Age and gender were entered as covariates in the models.
HOMA-IR, homeostasis model assessment of insulin resistance; ß ± SE, regression coefficient ± standard error; stand, standardized; pR, partial 
correlation coefficient; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Table 3: Associations between aminotransferase concentrations 
and metabolic Syndrome features
Metabolic syndrome features ALT (u/l) AST (u/l)
Rp Rp
Log HOMA-IR (uU.mmol/ml.l) 0.54 < 0.0001 0.36 0.001
Glucose (mmol/l) 0.20 0.09 0.11 0.4
Waist circumference (cm) 0.41 0.0002 0.09 0.4
Log triglycerides (mmol/l) 0.42 0.0002 0.37 0.001
HDL cholesterol (mmol/l) -0.12 0.3 0.01 0.9
Systolic blood pressure (mmHg) 0.01 0.9 -0.05 0.7
Diastolic blood pressure (mmHg) 0.07 0.5 -0.03 0.8
ALT, alanine aminotransferase; AST, aspartate aminotransferase; Log, 
logarithmically transformed; HOMA-IR, homeostasis model 
assessment of insulin resistance.BMC Cardiovascular Disorders 2007, 7:31 http://www.biomedcentral.com/1471-2261/7/31
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syndrome [1,2,19]. As further shown in Figure 1 and as
compared to aminotransferase concentrations, waist cir-
cumference was not associated with plaque whereas the
HOMA-IR was associated with plaque in univariate analy-
sis but no longer (p = 0.08) after age, gender, hyperten-
sion and hypothyroidism were controlled for. After
adjustment for the Framingham score, the HOMA-IR was
associated with plaque (OR [95% CI] = 1.80 [1.12–2.91]
(p = 0.02) for 1 SD increase in HOMA-IR) whereas waist
circumference was not associated with plaque (OR [95%
CI] = 1.29 [0.77–2.17] (p = 0.3) for 1 SD increase in waist
circumference). Adjusted for alcohol intake and changes
in weight on MTX did not materially affect these associa-
tions (p = 0.02 for HOMA-IR and p = 0.3 for waist circum-
ference). Further, after adjustment for ALT or AST
concentrations, the HOMA-IR was no longer associated
with plaque (p ≥ 0.1).
Disease activity and inflammation enhance cardiovascu-
lar risk in RA [31,32]. In this cohort, C-reactive protein
concentrations were not associated with carotid artery
intima-media thickness (R = 0.08, p = 0.5) or plaque (C-
reactive protein = 9.4 [5.8–15.5] mg/dl in those with
plaque and 6.7 [4.4–10.2] mg/dl in those without plaque
(p = 0.3)). This may be related to the fact that only one
measurement of C-reactive protein in time was considered
and to our small sample size. Also, after adjustment for C-
reactive protein concentrations, ALT, AST and the HOMA-
IR remained associated with plaque (OR [95% CI] = 1.87
[1.11–3.18] (p = 0.02), 1.89 [1.15–3.11] (p = 0.01) and
1.80 [1.12–2.89] (p = 0.01) for 1 SD increase in ALT, AST
and HOMA-IR, respectively).
Discussion
In this study we found, for the first time, that high serum
aminotransferase concentrations were associated with the
presence of carotid artery plaque independent of age, gen-
der, hypertension and hypothyroidism, and of conven-
tional cardiovascular risk factors as estimated by the
Framingham score. Whereas NAFLD is a potentially newly
identified pathogenetic mechanism in the metabolic syn-
drome [21,38] and cardiovascular disease, abdominal
adiposity and insulin resistance are the most recognized
pathogenetic pathways in the metabolic syndrome
[1,2,19]. We found no association between waist circum-
ference and plaque. This finding is in keeping with previ-
ous reports on cardiovascular disease in RA [16,17] and
argues against the use of waist circumference as an alter-
native to insulin resistance in the assessment of cardiovas-
cular risk in this disease. Importantly, in univariate
analysis, the odds ratios for plaque were very similar at
1.92, 1.93 and 1.82 for 1 SD increase in ALT (~10 u/l) and
AST concentrations (~6 u/l) and in HOMA-IR (~0.2
uU.mmol/ml.l), respectively, with extensively overlap-
ping 5 to 95% confidence intervals for these 3 metabolic
parameters. Moreover, whereas AST concentrations were
associated with plaque independent of insulin resistance,
the HOMA-IR was not associated with plaque independ-
ent of AST concentrations. Taken together, serum ami-
notransferase concentrations performed at least as well as
insulin resistance as assessed by the HOMA-IR in the iden-
tification of the presence of carotid artery atherosclerosis
in this RA cohort.
In our analysis, aminotransferase concentrations contrib-
uted as much as waist circumference to the variability in
insulin resistance. This suggests that the determination of
aminotransferase concentrations can make a valuable
additional contribution to waist circumference measure-
ments in the identification of subjects with insulin resist-
ance, a risk factor not only for cardiovascular disease but
also for type 2 diabetes mellitus [1,2,19]. Both directly
estimated liver fat content and high aminotransferase
concentrations are reportedly strongly associated with
metabolic syndrome features in individuals without RA
[21-23]. In the present cohort, a consistent relationship
between aminotransferase concentrations and triglycer-
ides and the HOMA-IR was found. AST concentrations
may reflect liver fat content less reliably than ALT levels
since liver fibrosis can also contribute to high AST concen-
trations [20]. ALT concentrations were associated with
waist circumference whereas AST concentrations were not.
Our finding of an association of aminotransferase concen-
trations with metabolic syndrome features suggests that
Associations of aminotransferases, HOMA-IR and waist cir- cumference with ultrasonographically located carotid artery  plaque in logistic regression models Figure 1
Associations of aminotransferases, HOMA-IR and waist cir-
cumference with ultrasonographically located carotid artery 
plaque in logistic regression models. *Adjusted for age, gen-
der, hypertension and hypothyroidism. SD, standard devia-
tion; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; HOMA-IR, homeostasis model assessment 
of insulin resistance; CI, confidence interval.
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high aminotransferases are caused by NAFLD [23]. We
considered an extensive range of potentially confounding
variables including used medications, in our analyses.
Once other causes of chronic liver disease are excluded,
non-alcoholic fatty liver disease is the cause of asympto-
matic elevations of aminotransferase levels in 90% of
cases [20] and magnetic resonance spectroscopy quanti-
fied liver fat content correlates with ALT concentrations in
non-RA subjects (r = 0.4 to 0.6, p < 0.001) [22]. However,
we did not directly estimate liver fat content and, there-
fore, whether high aminotransferase concentrations
reflect NAFLD in patients with RA as applies to non-RA
subjects, needs to be determined.
The use of current metabolic syndrome definitions and
even the existence of the metabolic syndrome have
recently been questioned [40]. This issue has also been
addressed in previously RA studies [16,17]. These reports
together with our current findings argue for considering
both insulin resistance and aminotransferase concentra-
tions as metabolic syndrome features in cardiovascular
risk stratification in RA. Notably, these characteristics do
not form part of the NCEP: ATP III and International Dia-
betes Federation defined metabolic syndrome [1,18].
We found that mean ALT and AST levels were 27 u/l and
25 u/l in patients with plaque, respectively. The corre-
sponding values for ALT and AST in patients without
plaque were each 20 u/l. Further, levels of > 23 u/l for ALT
and 22 u/l for AST (95% CI values in patients without
plaque) were associated with a 4-fold increased preva-
lence of plaque. Thus, methotrexate naïve RA patients
with ALT concentrations > 23 u/l or/and AST concentra-
tions > 22 u/l were at high risk of having severe atheroscle-
rosis, thereby suggesting that RA patients with
aminotransferase levels above these cut points require fur-
ther evaluation for the presence of atherosclerosis. Such
patients may further benefit from interventions that are
recommended in NAFLD [20-24]. These aspects need to
be addressed in future larger studies. Such levels of ami-
notransferases are well within normal reference ranges
used in our laboratory. Indeed, Prati and colleagues [39]
reported that most patients with non-alcoholic fatty liver
disease or chronic asymptomatic hepatitis C virus infec-
tion have ALT concentrations that are within currently rec-
ommended reference ranges, and showed that a reduction
of upper limits for ALT to 19 u/l in women and 30 u/l in
men increased the sensitivity in identifying hepatitis C
viremia from 55% to 76% with an acceptable reduction in
specificity from 97% to 89%.
We investigated a cohort of RA patients. Since the preva-
lence of both cardiovascular disease and insulin resistance
is increased in RA [8-15], our results need to be confirmed
in subjects without RA. Whereas methotrexate use in RA is
associated with both a marked reduction in cardiovascular
mortality [41] and increased aminotransferase concentra-
tions, in contrast to our findings prior to methotrexate
therapy, we no longer found an association between ami-
notransferase levels and atherosclerosis once methotrex-
ate had been initiated. Our findings also do not support
the use of aminotransferase concentrations in the identifi-
cation of elevated cardiovascular risk once on methotrex-
ate. We did not assess the hepatitis B surface antigen and
hepatitis C antibody status in patients with ALT or AST
levels below normal reference ranges as used in our labo-
ratory. However, both hepatitis B and C infection occur
infrequently in South African Caucasians and Asians [42].
We measured insulin resistance using the HOMA-IR
rather than the hyperinsulinemic euglycemic clamp tech-
nique, and abdominal obesity was estimated by waist cir-
cumference and not by computed tomography or
magnetic resonance imaging. Conversely, characteristics
as recorded in this study are often accessible in routine
clinical care settings. As in investigations previously
reported by us, we defined plaque as a localized irregular
intima-media thickening of ≥1.5 mm [16,28,43,44]
whereas others considered plaque to be present when a
≥50% protrusion beyond the diameter of the surrounding
wall was found (eg. Roman et al [45]). The mean com-
mon carotid artery intima-media thickness was 0.73 mm
in our patients with plaque. In a RA cohort of 91 subjects,
we recently identified 6 cardiovascular risk factors that
were independently associated with plaque [44]. This
compares favorably to the study of Roman et al in which
only 3 independent risk factors for atherosclerosis were
identified in 98 RA patients [45]. The optimal criteria for
defining the presence of plaque in RA deserve further
study in larger cohorts. Finally, one could argue that it
would be more straightforward to perform imaging stud-
ies since liver enzymes are not directly involved in athero-
genesis. However, in contrast to the determination of
aminotransferase concentrations, carotid ultrasonogra-
phy is currently not routinely performed in patients with
RA.
Conclusion
Our findings suggest that, within currently recommended
reference ranges, high aminotransferase concentrations
may be strongly associated with insulin resistance in RA.
Moreover, such aminotransferase elevations were closely
associated with atherosclerosis. Whether determination of
aminotransferase concentrations is a useful tool in the
assessment of cardiovascular risk in patients with RA
awaits replication of our results in other settings and in
different populations with larger sample sizes.
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